Michael J. Thirman

机构：University of Illinois Chicago, University of Chicago · ORCID：0000-0001-5154-9499

发表论文 241 篇 · 总被引 11819 次 · h-index 49

代表论文

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model (2025 · Leukemia · 被引 12)
Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study (2025 · Blood · 被引 5)
Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies (2026 · American Journal of Hematology · 被引 2)
Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (2025 · Blood · 被引 2)
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies (2025 · British Journal of Haematology · 被引 2)
Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study (2025 · Blood · 被引 1)